Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II HSCT from HLA-matched donor using post-transplant cyclophosphamide
jRCTs031180140Phase 2Completed
- Sponsor
- University of Tsukuba Hospital
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by University of Tsukuba Hospital. Primary endpoint: Success rate at 6 months. Started Oct 2018; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs031180140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180140.